Athera Biotechnologies

Athera Biotechnologies develops drugs with the potential to improve treatment of patients with cardiovascular disease. The treatment concept is based on pioneering research results that highlight the link between low levels of specific biomarkers and the risk of developing atherosclerosis. Athera has identified, selected and patented the PC-mAb antibody that has been shown to have interesting biological and medicinal effects, and has also developed a robust production method.

The project is currently undergoing phase I trials in patients with severe peripheral artery disease who have undergone vein graft surgery. Athera has also developed a CE-approved test to identify those patients who are most likely to benefit from drug treatment using PC-mAb.

Athera Biotechnologies at a glance

What they do: Develops new drugs and diagnostic tools to prevent and treat cardiovascular diseases
Founded in: 2005
Head quarters: Stockholm, Sweden
www.athera.se

By continuing to interact with the site, you agree to the use of cookies. More information

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.

Close